Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587352 · ClinicalTrials.gov registry record · Phase 2
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
A Phase 2 study of Metastatic Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT01587352 is a Phase 2 study of Metastatic Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01587352, a Phase 2 study of Metastatic Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Vorinostat
Study Locations (3)
New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-05-29 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01587352
The ClinicalTrials.gov registry entry for NCT01587352 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (69% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01587352 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01587352 about?
NCT01587352 is a clinical study titled "Vorinostat in Treating Patients With Metastatic Melanoma of the Eye". This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01587352?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-05-29. Estimated completion is 2026-12-31.
What conditions does trial NCT01587352 study?
This clinical trial studies the following conditions: Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7.
What interventions are being tested in trial NCT01587352?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT01587352?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01587352 being conducted?
This trial has 3 study locations across New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.